VC be­liev­ers back a $41M game plan for En­ter­prise Ther­a­peu­tic­s' new group of res­pi­ra­to­ry drugs

Alex May­weg wasn’t at­tract­ed to the team at En­ter­prise Ther­a­peu­tics be­cause they had some new, cut­ting-edge tech­nol­o­gy that would set the biotech world on fire. The Ver­sant part­ner, and for­mer top glob­al chemist at Roche, had no eu­re­ka mo­ment.

In­stead, he was just deeply im­pressed by a group of ex­pe­ri­enced vet­er­ans with a han­dle on ion chan­nel R&D work which could play a key role in con­trol­ling the mu­cus buildup that be­dev­ils a large group of pa­tients for a range of res­pi­ra­to­ry dis­eases like cys­tic fi­bro­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER